Menu
Recruiting NCT04343365

Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board

— Observational Incurable Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Evolutionary Tumor Board (ETB).
Who it may be relevant to
Registry conditions: Incurable Disease. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Feasibility of Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board in Cancer Patients

Overview

This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.

Interventions

  • Other Evolutionary Tumor Board (ETB)
    The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and resul

Primary outcome measures

  • ETB developing therapeutic strategies [Time frame: Baseline to up to 60 months from end of therapy]

Eligibility criteria

Inclusion criteria

  • Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
  • Participant must have a life expectancy greater than 3 months
  • Participant must have an ECOG performance status 0-2
  • Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
  • Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.

Exclusion criteria

  • None

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

United States · 1 center
  • Moffitt Cancer Center — Tampa

Identifiers

NCT: NCT04343365 · MCC-20417

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗